This study traces the clonal evolution of pancreatic cancer from IPMN using genomic and transcriptomic data, identifying two distinct evolutionary trajectories and their implications for PDAC progression.

Nature Communications · Mar 4, 2026Peer-reviewedCancer Biology

Morphospatial profiling of cancer-associated fibroblasts reveals architectural subtypes of pancreatic ductal adenocarcinoma

Adam S. Bryce, Silvia Martinelli, Leonor Schubert Santana, Leah Officer-Jones, Rachel L. Baird, Fiona Ballantyne, Kai Rakovic, Ian R. Powley, Dina Tataran, David J. Meltzer, Christopher Walsh, Fraser Duthie, Lucas Farndale, Adalberto Claudio Quiros, Ke Yuan, , David Kuang-Fu Chang

This study identifies architectural subtypes of PDAC using morphospatial profiling of CAFs, showing improved prognostication and chemotherapy response prediction.

bioRxiv · Feb 9, 2026 · PreprintCancer Biology

Sequential ATR and PARP Inhibition Overcomes Acquired DNA Damaging Agent Resistance in Pancreatic Ductal Adenocarcinoma

Katharine J. Herbert, Rosanna Upstill‐Goddard, Stephan B. Dreyer, Selma Rebus, Australian Pancreatic Cancer Genome Initiative, Christian P. Pilarsky, Debabrata Mukhopadhyay, Christopher J. Lord, Genomics Innovation Alliance, Andrew Victor Biankin, Fieke E. M. Froeling, David Kuang-Fu Chang

This study shows that sequential ATR and PARP inhibition can overcome acquired resistance to DNA damaging agents in pancreatic ductal adenocarcinoma.

British Journal of Cancer · May 29, 2025Peer-reviewedCancer Biology